Parallel-group controlled trial of intranasal esketamine (0.5 mg/kg) vs saline placebo in lung-cancer surgery patients with a long smoking history (≥20/day × 5+ years) undergoing smoking cessation. Target: 80 participants (40/40). Primary outcomes: HDRS-24, MADRS, CADSS, BPRS. Sponsor: Zhejiang Provincial People's Hospital, Hangzhou, China.
Intranasal delivery of esketamine (ESK) once a week for 8 sessions.
Administered once a week for 8 sessions
Intranasal delivery of normal saline placebo once a week for 8 sessions.
Normal saline placebo with a bittering agent added to simulate the taste of esketamine